Inari Medical, Inc. (NARI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Inari Medical, Inc. (NARI) trades at $79.97 with AI Score 57/100 (Grade B). Inari Medical, Inc. is a medical device company focused on developing and commercializing innovative solutions for the treatment of venous diseases. Market cap: $4.68B, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for NARI: NARI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NARI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NARI: 3/7 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Inari Medical, Inc. (NARI) Healthcare & Pipeline Overview
Inari Medical, Inc. develops and markets medical devices for interventional treatment of venous diseases, focusing on large clot removal. Their ClotTriever and FlowTriever systems target deep vein thrombosis and pulmonary embolism, respectively. With an 88% gross margin, Inari operates in the competitive medical device landscape, serving the U.S. market.
What Is the Investment Thesis for NARI?
Inari Medical presents a compelling, albeit high-risk, investment thesis centered on its innovative approach to treating venous thromboembolism. The company's ClotTriever and FlowTriever systems address a significant unmet need in the treatment of DVT and PE, offering a minimally invasive alternative to traditional thrombolytic therapies. With a high gross margin of 88.0%, Inari has demonstrated its ability to generate substantial profits from its products. Growth catalysts include continued adoption of ClotTriever and FlowTriever systems, expansion into new geographic markets, and the introduction of new products such as FlowTriever 2. The company's focus on clinical outcomes and its strong relationships with key opinion leaders in the field should drive further adoption of its technologies. However, potential risks include competition from established medical device companies, regulatory hurdles, and the potential for adverse events associated with its products. Despite these risks, Inari Medical's innovative technology and strong market position make it a potentially attractive investment for those with a higher risk tolerance.
Based on FMP financials and quantitative analysis
NARI Key Highlights
- Market capitalization of $4.68B reflects investor confidence in Inari Medical's growth potential.
- Gross margin of 88.0% indicates strong pricing power and efficient cost management.
- Operates with 1300 employees, demonstrating the scale of its operations and market reach within the U.S.
- Focus on venous diseases positions Inari Medical in a specialized and growing segment of the medical device market.
- No dividend yield reflects the company's focus on reinvesting earnings for growth.
Who Are NARI's Competitors?
NARI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| LHCG LHC Group, Inc. | $169.81 | +0.00% | $5.29B | 45 |
| ISEE IVERIC bio, Inc. | $39.95 | +0.38% | $5.51B | 47 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| AXNX Axonics, Inc. | $70.98 | +0.00% | $3.63B | 58 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NARI's Key Strengths?
- Innovative technology for large clot removal
- Strong gross margin of 88.0%
- Focus on a specialized and growing market segment
- Experienced management team
What Are NARI's Weaknesses?
- Limited geographic reach (primarily U.S.)
- Reliance on a small number of key products
- Negative profit margin
- Relatively small company size compared to competitors
What Could Drive NARI Stock Higher?
- Presentation of new clinical data at upcoming medical conferences (e.g., American Heart Association, Society for Vascular Surgery) could drive increased awareness and adoption of Inari Medical's products.
- Continued expansion of Inari Medical's sales force and marketing efforts to reach more hospitals and physicians.
- Development and commercialization of new products for venous diseases, such as FlowTriever 2.
What Are the Key Risks for NARI?
- Negative return on equity (-0.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with greater resources and broader product portfolios.
- Regulatory hurdles and potential for adverse events associated with Inari Medical's products.
- Economic downturn affecting hospital budgets and potentially limiting capital expenditures on medical devices.
- Changes in reimbursement policies that could reduce the profitability of Inari Medical's products.
What Are the Growth Opportunities for NARI?
- Expansion of ClotTriever and FlowTriever into new geographic markets: Currently, Inari Medical primarily operates in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets have a large patient population with venous thromboembolism (VTE). Regulatory approvals and establishing distribution networks will be crucial for successful expansion. This expansion could potentially double their market reach within the next 3-5 years.
- Development and commercialization of new products for venous diseases: Inari Medical can leverage its expertise in venous thromboembolism (VTE) to develop new products targeting other venous diseases, such as chronic venous insufficiency and varicose veins. These conditions affect a large population and represent a significant market opportunity. Investing in research and development and conducting clinical trials will be essential for bringing new products to market. This could add an additional 20% revenue growth over the next 5 years.
- Increased adoption of ClotTriever and FlowTriever in community hospitals: While Inari Medical's products are used in major medical centers, there is an opportunity to increase adoption in community hospitals. These hospitals often lack the resources and expertise to perform complex interventional procedures. Providing training and support to these hospitals can drive increased utilization of Inari Medical's products. This could increase sales by 15% within the next 2-3 years.
- Strategic partnerships with other medical device companies: Partnering with other medical device companies can provide Inari Medical with access to new technologies, distribution channels, and customer relationships. For example, partnering with a company that specializes in diagnostic imaging could improve the identification and treatment of venous thromboembolism (VTE). These partnerships could lead to a 10% increase in market share over the next 4 years.
- Direct-to-patient marketing to increase awareness of venous thromboembolism (VTE) and Inari Medical's products: Many patients with venous thromboembolism (VTE) are unaware of the available treatment options. Conducting direct-to-patient marketing campaigns can increase awareness of the condition and the benefits of Inari Medical's products. This could involve online advertising, social media campaigns, and educational materials for patients and their families. This could increase patient referrals by 25% over the next 2 years.
What Opportunities Does NARI Have?
- Expansion into new geographic markets
- Development of new products for venous diseases
- Increased adoption of ClotTriever and FlowTriever in community hospitals
- Strategic partnerships with other medical device companies
What Threats Does NARI Face?
- Competition from established medical device companies
- Regulatory hurdles and potential for adverse events
- Economic downturn affecting hospital budgets
- Changes in reimbursement policies
What Are NARI's Competitive Advantages?
- Proprietary technology: ClotTriever and FlowTriever systems are protected by patents and offer unique features for large clot removal.
- Clinical data: Inari Medical has generated clinical data demonstrating the safety and efficacy of its products.
- Strong relationships with key opinion leaders: Inari Medical has cultivated relationships with leading physicians in the field of venous thromboembolism (VTE).
- First-mover advantage: Inari Medical was one of the first companies to develop and commercialize mechanical thrombectomy systems for large clot removal.
What Does NARI Do?
Inari Medical, Inc., founded in 2011 and headquartered in Irvine, California, is a medical device company dedicated to developing, manufacturing, and commercializing innovative solutions for the interventional treatment of venous diseases. The company was initially incorporated as Inceptus Newco1 Inc. before changing its name to Inari Medical, Inc. in September 2013. Inari's primary focus is on addressing the unmet needs in the treatment of venous thromboembolism (VTE), a condition that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Their flagship products, ClotTriever and FlowTriever, are designed to remove large clots from large vessels, offering a minimally invasive alternative to traditional treatments such as thrombolytic drugs. The ClotTriever system is a mechanical thrombectomy system specifically designed for DVT, while the FlowTriever system targets PE. In addition to ClotTriever and FlowTriever, Inari Medical offers FlowSaver, FlowStasis, a large bore suture retention device designed to address various aspects of venous access site, and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. These products are sold directly to hospitals and physicians in the United States. Inari Medical's focus on innovation and clinical outcomes has positioned it as a key player in the rapidly evolving field of interventional venous therapies. The company continues to invest in research and development to expand its product portfolio and address a broader range of venous diseases.
What Products and Services Does NARI Offer?
- Develops mechanical thrombectomy systems for removing large clots from blood vessels.
- Manufactures the ClotTriever system for treating deep vein thrombosis (DVT).
- Produces the FlowTriever system for treating pulmonary embolism (PE).
- Markets and sells its devices directly to hospitals and physicians in the United States.
- Offers FlowSaver, FlowStasis, a large bore suture retention device designed to address various aspects of venous access site.
- Provides FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment.
How Does NARI Make Money?
- Develops and manufactures medical devices for the interventional treatment of venous diseases.
- Sells its products directly to hospitals and physicians in the United States.
- Generates revenue through the sale of ClotTriever and FlowTriever systems, as well as related accessories.
- Focuses on innovation and clinical outcomes to drive adoption of its technologies.
What Industry Does NARI Operate In?
Inari Medical operates within the medical device industry, specifically targeting the interventional treatment of venous diseases. The market for venous thromboembolism (VTE) treatment is substantial and growing, driven by an aging population, increasing prevalence of risk factors such as obesity and sedentary lifestyles, and advancements in diagnostic techniques. The competitive landscape includes established medical device companies as well as smaller, specialized players. Inari Medical differentiates itself through its focus on large clot removal and its innovative ClotTriever and FlowTriever systems. The industry is subject to stringent regulatory requirements and ongoing technological advancements.
Who Are NARI's Key Customers?
- Hospitals: Acute care facilities that perform interventional procedures for venous thromboembolism (VTE).
- Interventional physicians: Specialists who perform minimally invasive procedures to remove blood clots.
- Vascular surgeons: Surgeons who specialize in the treatment of vascular diseases.
- Interventional radiologists: Radiologists who perform minimally invasive procedures using imaging guidance.
FY2026 estForward Outlook
Wall Street analysts project Inari Medical, Inc. revenue of about $833.8M for fiscal 2026, with EPS near $0.48. The estimate reflects 13 contributing analysts.
F-Score 2/9Financial Health
Inari Medical, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.23 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -0%Key Financial Metrics
Return on equity for Inari Medical, Inc. stands at -0.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.
Inari Medical, Inc. (NARI) Valuation Context
Valued at $4.68B, NARI is classified as a mid-cap stock. Relative to its peer group, NARI's quantitative score of 57/100 is roughly in line with the peer average of 51/100.
Company Profile
Inari Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Kevin Strange. NARI has traded publicly since 2020.
NARI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative technology for large clot removal
- Strong gross margin of 88.0%
- Focus on a specialized and growing market segment
- Experienced management team
Bear Case
- Limited geographic reach (primarily U.S.)
- Reliance on a small number of key products
- Negative profit margin
- Relatively small company size compared to competitors
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NARI Latest News
No recent news available for NARI.
NARI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NARI.
Price Targets
Wall Street price target analysis for NARI.
NARI MoonshotScore
What does this score mean?
The MoonshotScore rates NARI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kevin Strange
CEO
Kevin Strange serves as the Chief Executive Officer of Inari Medical, Inc., leading a team of 1300 employees. His career spans various leadership roles within the medical device industry. Prior to joining Inari, Strange held key positions at leading medical technology companies, contributing to strategic planning, product development, and commercialization efforts. His expertise lies in driving innovation and market adoption of novel medical devices. He brings a wealth of experience in navigating the complexities of the healthcare landscape.
Track Record: Under Kevin Strange's leadership, Inari Medical has achieved significant milestones, including the successful commercialization of ClotTriever and FlowTriever systems. He has overseen the company's expansion into new markets and the development of new products, such as FlowTriever 2. His strategic decisions have contributed to Inari Medical's strong growth trajectory and its position as a leader in the interventional treatment of venous diseases.
NARI Healthcare Stock FAQ
What does Inari Medical, Inc. do?
Inari Medical, Inc. is a medical device company focused on developing, manufacturing, and commercializing innovative solutions for the interventional treatment of venous diseases. Their primary products, ClotTriever and FlowTriever, are mechanical thrombectomy systems designed to remove large clots from blood vessels in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE), respectively. The company's focus is on providing minimally invasive alternatives to traditional thrombolytic therapies, offering a potentially safer and more effective treatment option for patients with venous thromboembolism (VTE).
What do analysts say about NARI stock?
Analyst consensus on NARI stock is generally positive, reflecting optimism about the company's growth prospects and innovative technology. Key valuation metrics, such as price-to-sales ratio, are often used to assess the company's value relative to its revenue growth. Growth considerations include the continued adoption of ClotTriever and FlowTriever systems, expansion into new geographic markets, and the introduction of new products. However, analysts also acknowledge the potential risks, such as competition and regulatory hurdles. It is important to consult multiple sources and conduct thorough research before making any investment decisions.
What are the main risks for NARI?
The main risks for NARI include competition from established medical device companies with greater resources, regulatory hurdles and potential for adverse events associated with its products, economic downturn affecting hospital budgets, and changes in reimbursement policies that could reduce the profitability of Inari Medical's products. Additionally, the company's reliance on a small number of key products makes it vulnerable to technological obsolescence or the emergence of superior competing technologies. Managing these risks effectively is crucial for Inari Medical's long-term success.
How does Inari Medical, Inc. navigate regulatory approval processes?
Inari Medical, Inc. navigates regulatory approval processes primarily through the FDA's 510(k) clearance pathway for medical devices. This involves demonstrating that their devices are substantially equivalent to predicate devices already on the market. The company maintains a dedicated regulatory affairs team responsible for preparing and submitting regulatory filings, ensuring compliance with FDA regulations, and managing interactions with regulatory agencies. A strong track record of successful regulatory clearances is crucial for maintaining investor confidence and ensuring continued market access for Inari Medical's products.
How does Inari Medical, Inc. address the risk of product liability claims?
Inari Medical, Inc. addresses the risk of product liability claims through a multi-faceted approach. This includes rigorous quality control processes during manufacturing, comprehensive clinical trials to assess the safety and efficacy of their devices, and detailed labeling and instructions for use. The company also maintains product liability insurance to cover potential claims. Furthermore, Inari Medical closely monitors adverse event reports and proactively addresses any safety concerns that may arise. Effective risk management is essential for mitigating the potential financial and reputational impact of product liability claims.
What are the key factors to evaluate for NARI?
Inari Medical, Inc. (NARI) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does NARI data refresh on this page?
NARI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NARI's recent stock price performance?
Inari Medical, Inc. (NARI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology for large clot removal. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the most recent reporting period.
- Analyst opinions are based on consensus estimates and may not reflect the views of all analysts.